Explore

Trendline Trendline
Summit Therapeutics Faces High Volatility Amid Lung Cancer Drug Trial Optimism

Summit Therapeutics Faces High Volatility Amid Lung Cancer Drug Trial Optimism

Summit Therapeutics Faces High Volatility Amid Lung Cancer Drug Trial Optimism
Trendline Trendline
Halia Therapeutics Reports Positive Phase 2a Results for Ofirnoflast in MDS Treatment

Halia Therapeutics Reports Positive Phase 2a Results for Ofirnoflast in MDS Treatment

Halia Therapeutics Reports Positive Phase 2a Results for Ofirnoflast in MDS Treatment
Trendline Trendline
CLINUVEL Expands Singapore RD Centre to Advance Peptide Therapies

CLINUVEL Expands Singapore RD Centre to Advance Peptide Therapies

CLINUVEL Expands Singapore RD Centre to Advance Peptide Therapies
Trendline Trendline
CLINUVEL Expands Singapore Facility to Advance Peptide Therapies

CLINUVEL Expands Singapore Facility to Advance Peptide Therapies

CLINUVEL Expands Singapore Facility to Advance Peptide Therapies
Trendline Trendline
Tech Leaders Advocate for Autonomous Start-Up Cities to Foster Innovation

Tech Leaders Advocate for Autonomous Start-Up Cities to Foster Innovation

Tech Leaders Advocate for Autonomous Start-Up Cities to Foster Innovation
Rapid Read Rapid Read
Biogen and Stoke Therapeutics Report Promising Results for Epilepsy Drug Zorevunersen

Biogen and Stoke Therapeutics Report Promising Results for Epilepsy Drug Zorevunersen

Biogen and Stoke Therapeutics have announced promising results from their investigational drug zorevunersen, which is being developed for the treatment of Dravet syndrome, a rare form of epilepsy. The companies presented data at the American Epilepsy Society meeting, showing that patients treated with zorevunersen experienced a significant reduction in major motor seizures. Specifically, a study revealed an 82% drop in seizures among patients receiving the drug, compared to a 20% reduction in a control group. The treatment also showed improvements in cognitive and behavioral measures. These findings suggest that zorevunersen could become a blockbuster drug, with potential regulatory activity expected next year.
Rapid Read Rapid Read
PureTech Advances Deupirfenidone for Idiopathic Pulmonary Fibrosis with FDA Support

PureTech Advances Deupirfenidone for Idiopathic Pulmonary Fibrosis with FDA Support

PureTech Health has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding its drug candidate deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (IPF). The FDA's feedback supports the advancement of deupirfenidone into a pivotal Phase 3 trial, which is set to begin in the first half of 2026. Deupirfenidone is being developed by Celea Therapeutics, a PureTech Founded Entity, and aims to become a new standard of care for IPF, a progressive and fatal lung disease. The Phase 3 SURPASS-IPF trial will compare deupirfenidone to pirfenidone, an existing FDA-approved therapy, to assess its efficacy and safety.
Rapid Read Rapid Read
NetraAI Platform Enhances Precision in Clinical Trials for Depression

NetraAI Platform Enhances Precision in Clinical Trials for Depression

The NetraAI platform, an explainable AI-driven tool, is being demonstrated in a phase II clinical trial for depression. This platform utilizes a dynamic machine learning approach to identify treatment-responsive patient subpopulations, addressing challenges in small, heterogeneous clinical trial datasets. NetraAI models placebo response as an informative variable, refining patient selection and optimizing drug efficacy analysis. The platform segments patient populations into clinically meaningful subpopulations, enhancing the precision of clinical trials. This approach aims to improve the identification of patients who are most likely to benefit from specific treatments, thereby increasing the efficiency and effectiveness of clinical trials.
Rapid Read Rapid Read
EpiVax and FDA Study Highlights Immunogenicity Risks in Generic Teriparatide

EpiVax and FDA Study Highlights Immunogenicity Risks in Generic Teriparatide

EpiVax, in collaboration with the FDA and CUBRC, has published a study assessing the immunogenicity risks of peptide-related impurities in generic teriparatide products. The study utilized computational and experimental methods to evaluate the potential for these impurities to trigger unwanted immune responses. Findings indicated that certain impurities had higher predicted immunogenic potential than the reference teriparatide sequence, which could impact the safety and efficacy of generic peptide drugs. The study provides a framework for assessing and mitigating immunogenicity risks in generic peptide development.
Rapid Read Rapid Read
Singapore Faces Rising Demand for Digital-ESG Talent Amid Workforce Evolution

Singapore Faces Rising Demand for Digital-ESG Talent Amid Workforce Evolution

The Asia-Pacific talent landscape is shifting, with employees prioritizing flexibility, purpose, and long-term growth over salary. This change is driven by rising expectations, tighter skills supply, and evolving business priorities. In Singapore, demand for roles in e-commerce, data analytics, sustainability reporting, and supply chain optimization is surging. Foreign manpower controls and expanding ESG requirements intensify competition for talent with digital fluency and ESG literacy. Younger professionals, particularly Gen Z and millennials, seek meaningful work and supportive leadership, prompting employers to reevaluate their value propositions.
Rapid Read Rapid Read
Aleta Biotherapeutics and Cancer Research UK Report Promising Results in B-Cell Malignancy Trial

Aleta Biotherapeutics and Cancer Research UK Report Promising Results in B-Cell Malignancy Trial

Aleta Biotherapeutics, in collaboration with Cancer Research UK's Centre for Drug Development, has announced promising results from a phase I/II clinical trial of their CAR T-cell engager biologic, ALETA-001. The trial targets patients with B-cell malignancies who have previously undergone anti-CD19 CAR T-cell therapy. The study, conducted across multiple sites in the UK, aims to evaluate the safety and efficacy of ALETA-001. Preliminary findings indicate a highly tolerable safety profile and encouraging efficacy responses in patients with refractory or relapsed disease. The trial involves dose escalation to determine the optimal dose for further study. The results suggest that ALETA-001 can enhance the effectiveness of existing CAR T-cell therapies by increasing CD19 antigen density, potentially offering a new therapeutic option for patients who relapse after initial CAR T-cell treatment.
Rapid Read Rapid Read
Michael J. Fox Foundation Launches Initiative for Parkinson's Disease Therapeutics

Michael J. Fox Foundation Launches Initiative for Parkinson's Disease Therapeutics

The Michael J. Fox Foundation for Parkinson's Research (MJFF) has announced the launch of its Targets to Therapies (T2T) Initiative, aimed at advancing new biological targets for Parkinson's disease treatments. This multi-year program involves collaboration with scientists from academia, industry, and venture capital to reduce the risks associated with therapeutic development. Over 280 targets were evaluated, resulting in 21 priority targets for validation. The initiative has begun funding multidisciplinary teams to validate these targets, focusing on mechanisms like NOD2 and OGA, which are crucial for addressing Parkinson's disease processes.